Currently Viewing
AACR update: New immunotherapy drug shows benefit in lung cancer
April 09, 2014 – Debu Tripathy
So much to celebrate
March 25, 2014 – Guest
Adding surgery in metastatic kidney cancer could improve survival
March 21, 2014 – Elizabeth Whittington
Inflammation and fatigue
March 21, 2014 – Kathy LaTour
The Little Couple has cancer
March 20, 2014 – Kathy LaTour
Increased screening leads to decrease in colorectal cancer
March 18, 2014 – Elizabeth Whittington
Lynch Syndrome Awareness Day: March 22
March 18, 2014 – Elizabeth Whittington
Healing Sounds of Music Therapy
March 17, 2014 – Amy Rushlow
Blood Pressure Meds Help Hypertensive Patients With Kidney Cancer
March 17, 2014

AACR update: New immunotherapy drug shows benefit in lung cancer

BY Debu Tripathy
PUBLISHED April 09, 2014
Debu Tripathy blog image
One of the areas that has progressed quite a bit recently is that of tumor immunotherapy. At this year's annual meeting of the American Association for Clinical Research, several papers have been presented in this area. One of the most exciting is advances in lung cancer, which has been a traditionally hard to treat cancer. Recently there have been newer targeted therapies that work against growth factor receptors that show benefit, particularly in non-smokers. And now we're seeing advances in immunotherapy. Now, a fundamental breakthrough in immunology has come with understanding the controls of the immune cells that allows us augment the natural immune response that white cells have against tumors. One of the proteins blocked is the PD-1 receptor and PD-1 ligand. These proteins are important because the cancer cells can use them to block the immune system from attacking the cancer. There are several drugs being tested that inhibit this blockade, the so-called immune checkpoint, in trials not only for lung cancer, but also melanoma and other solid tumors. One of the potential benefits of one of these drugs called MK-3475 is that it may work in people who have a history of smoking, people who have traditionally not benefited from these targeted therapies. There is also some new information that we may be able to identify patients who have the best chance of responding to these drugs. There will be a more formal comparison and information on how the drug works in smokers coming hopefully very soon. We expect to hear those results at the annual ASCO meeting this summer. Debu Tripathy is an oncologist and editor-in-chief of CURE. He is the co-leader of the Women's Cancer Program at Norris Comprehensive Cancer Center and Professor of Medicine at the Keck School of Medicine at the University of Southern California.
Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In